Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
82143-0002-01 82143-0002 Bevacizumab-tnjn Avzivi 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan 1, 2025 In Use
66302-0014-01 66302-0014 Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 Intravenous Mar 10, 2015 In Use
59572-0425-21 59572-0425 Lenalidomide Revlimid 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 3, 2009 In Use
63459-0305-47 63459-0305 TRASTUZUMAB HERZUMA Immunotherapy Monoclonal Antibody HER2 Mar 16, 2020 In Use
69097-0381-73 69097-0381 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
60505-4534-02 60505-4534 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
57894-0514-01 57894-0514 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 2240.0 mg/14mL, 28000.0 mg/14mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
43598-0513-21 43598-0513 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
00115-1476-59 00115-1476 Imiquimod Imiquimod 50.0 mg/g Immunotherapy Immunomodulator Dermatological Agent Topical Feb 28, 2011 Jun 1, 2017 No Longer Used
59651-0345-07 59651-0345 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 6, 2023 In Use
57894-0510-01 57894-0510 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 1600.0 mg/10mL, 20000.0 mg/10mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
00007-3262-01 00007-3262 Tositumomab, Iodine I-131 Bexxar Therapeutic Immunotherapy Radioimmunotherapy CD20 Jul 15, 2009 Feb 20, 2014 No Longer Used
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sep 7, 2017 In Use
50242-0053-06 50242-0053 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 26, 1997 In Use
61314-0228-94 61314-0228 Denosumab WYOST 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jun 2, 2025 In Use
00085-1168-01 00085-1168 Interferon alfa-2b Intron A 11.6 ug/.5mL Immunotherapy Cytokine Interferon Intramuscular, Subcutaneous Jun 4, 1986 In Use
55513-0059-01 55513-0059 Tarlatamab-dlle IMDELLTRA (AMG757) 1.0 mg/1 Immunotherapy T Cell Receptor (TCR) DLL3, CD3 Intravenous May 16, 2024 In Use
76282-0701-48 76282-0701 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
00378-1941-21 00378-1941 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
59572-0210-95 59572-0210 Thalidomide Thalomid 100.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jun 20, 2003 In Use
00002-7678-01 00002-7678 Ramucirumab Cyramza 10.0 mg/mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 21, 2014 In Use
00024-0654-01 00024-0654 Isatuximab Sarclisa 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Mar 2, 2020 In Use
00085-0571-02 00085-0571 Interferon alfa-2b Intron A Immunotherapy Cytokine Interferon Jun 4, 1986 Jul 31, 2016 No Longer Used
00078-0690-61 00078-0690 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb 1, 2016 In Use
00074-1044-01 00074-1044 Telisotuzumab Vedotin EMRELIS 20.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use

Found 12159 results — Export these results